Ischemic cardiovascular disease associated with type 2 diabetes mellitus (T2DM) is characterized by the presence of relatively unstable coronary artery plaques with increased atheroma and intraplaque thrombus. The rupture of a plaque promotes the release of procoagulant material that stimulates the generation of an occlusive platelet-rich fibrin clot and, ultimately, the development of an acute coronary syndrome (ACS). The recognition of the importance of thrombus formation in the pathophysiology of cardiovascular disease led to a revolution in management that has culminated in markedly improved outcomes in both ACS and secondary prevention of cardiovascular disease.
Mechanisms in thrombosis
A major part of the problem facing diabetologists and cardiologists is that interactions between the metabolic milieu of T2DM and the bewildering array of inflammatory thrombotic molecules seem to underpin the cardiovascular phenotype. In simple terms, one can think of these processes as the fluid (circulating molecules) and cellular (platelet, endothelium, macrophages) phases that regulate clot formation. The fluid phase consists of the coagulation cascade, which, when activated, generates thrombin, which cleaves fibrinogen and activates Factor XIII to produce a fibrin mesh (Fig. 1) , which binds activated platelets. This early phase of activation produces the platelet-rich arterial thrombus that is characteristic of arterial occlusion. Latterly, activation of the fibrinolytic system regulates lysis and remodeling of the thrombus (Fig. 1 ) that physiologically, has an important role in wound healing, but in the peculiar circumstances of coronary artery occlusion is nearly always "too little, too late".
Interactions between diabetes on thrombosis
In the presence of T2DM, all the mechanisms described in the previous paragraph are abnormal. The principal drivers for these abnormalities are the combined effects of hyperglycemia and glycation and insulin resistance. In diabetes, increased thrombin generation related to increased activation of coagulation, the presence of underlying vascular disease, and hypoglycemia activates platelets, endothelial cells, and macrophages and promotes clot formation. [1] [2] [3] Glycation of fibrinogen in poorly controlled diabetes accentuates these effects by producing a densely packed fibrin clot that is also resistant to the effects of clot lysis. 4 Work from our laboratory has demonstrated that glycation of plasminogen reduces the catalytic activity of generated plasmin, further limiting the ability to lyse an established thrombus. 5 Finally, in the presence of insulin resistance, elevated levels of plasminogen activator inhibitor-1 further inhibit plasmin activity to effectively block clot lysis. 6 Putting this together, in the presence of diabetes there is increased generation of a tightly packed thrombus that is itself resistant to lysis, whereas the lytic processes are themselves inhibited. A bad combination.
The platelet and diabetes
It gets worse. The platelet in diabetes is increasingly activated due to a number of influences. First, loss of endothelial cell nitric oxide generation in the presence of insulin resistance leads to increased vasoconstriction and platelet activation. 7 Insulin resistance and hyperglycemia also have direct effects on the platelet, all combining to generate increased platelet activation. 8 Understanding this concatenation of events has led to the use of both anticoagulants and antiplatelet agents in the management of ACS, and antiplatelet agents in combination after ACS for secondary prevention. Although this approach has markedly reduced mortality in subjects with and without diabetes, there remains a currently unbridgeable gap in outcome between subjects with and without diabetes in which diabetes populations always fare worse. This gap is known as residual risk and, at the time of writing, the cause of this has not been clearly identified. A recent important paper from Monash University (Melbourne, Vic., Australia) has reported on an immature fraction of platelets, called reticulated platelets, and their regulation by glycaemia. 9 The reticulated platelets are large immature platelets that are intrinsically activated to a greater extent and have been shown to be resistant to the actions of antiplatelet agents. 10, 11 In hematology, these platelets are known to be increased in thrombocytopenic states, presumably to counter the increased bleeding risk associated with such conditions. It has been known for many years that diabetes is associated with an increase in this platelet fraction, but it has been largely ignored, perhaps considered of little importance. Recent evidence, in addition to indicating these platelets are resistant to inhibition, has also reported that this fraction is related to poorer outcomes after ACS. 12 Colleagues from Monash University have brought this topic to center stage in diabetes by demonstrating that suboptimal diabetes control increases the production of reticulated platelets and by reporting the mechanisms underpinning these effects and the potential reversibility by improved glycemic control. 9 The authors of that study reported that increased glycemia stimulates hepatic Kuppfer cells to release interleukin-6, which stimulates thrombopoietin production to increase the secretion of bone marrow-derived reticulated platelets, an effect reversed by improving glycemic control. 9 The available data indicates that an increased reticulated platelet count is associated with resistance to antiplatelet agents, increased cardiovascular risk, and, in diabetes, an effect that may be reversed by improving glycemic control. In addition to the abnormalities in clot formation and lysis described above, diabetes patients have alterations in platelet type and function, all of which promote the development of occlusive arterial disease and are resistant to the normal regulatory processes that limit clot formation.
Conclusion
Further understanding of these processes and in particular the importance of reticulated platelets in the clinical setting in T2DM may provide the opportunity to develop novel strategies to manage cardiovascular risk in both the acute setting and as secondary prevention. The Holy Grail of narrowing the residual risk in T2DM may lie in clarifying some of these issues.
PJG is co-Chair of the European Guidelines for Cardiovascular Disease Prevention and Management in Diabetes. The views expressed herein are the author's own and not those of the guideline committee. PJG has given lectures and been on advisory boards for Novo Nordisk, Amgen, Janssen Pharmaceuticals, Bayer, and Astra Zeneca. He is Editor-in-Chief of the International Journal of Diabetes and Cardiovascular Disease, and diabetes advisor for Synexus. Figure 1 Interactions between prothrombotic mechanisms and fibrinolysis. This schematic depicts the lower part of the coagulation cascade. Activation of coagulation Factor VII by tissue factor released from damaged cells leads to the formation of a "tenase" complex that cleaves prothrombin to generate thrombin. Thrombin has many functions, including platelet activation, but within the coagulation cascade it cleaves fibrinogen, activates Factor XIII, and initiates the formation of cross-linked fibrin, which, in the arterial circulation, binds platelets and forms a thrombus, leading to occlusive arterial disease. The fibrinolytic system acts to lyse and remodel the clot, which is an important role in tissue repair. In this system, tissue plasminogen activator (tPA) cleaves plasminogen to form plasmin, which breaks down fibrin. This system is inhibited at a number of places, notably by plasminogen activator inhibitor-1 (PAI-1) acting on tPA and by antiplasmin (not shown) inhibiting plasmin directly. Proteins in boxes are those affected by diabetes, as discussed in the text. (a,b) Electron micrographs of fibrin formed in vitro from the plasma of a non-diabetes subject (a) and an individual with diabetes that is poorly controlled (b). The micrograph in (b) shows a fibrin structure with thin, densely packed fibers that are resistant to the effects of fibrinolysis. FXIIIA, coagulation factor XIII.
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